Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

Stocks edged higher after their worst week since early September as the selloff in Treasuries abated, with traders keeping a close eye on news around President-elect Donald Trump’s administration.

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...

OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC ...

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...